Trial Profile

Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

08 Oct 2021 Results comparing vaccine efficacy of single dose to that of three and two doses in protecting against persistent HPV 16 and 18 infection at 10 years post vaccination, published in the Lancet Oncology.
23 Jul 2020 Results of pooled analysis of data from 2 trials (NCT00128661 and NCT00923702), assessing the serological assays to monitor antibody responses to single dose HPV vaccines, published in the Vaccine
31 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Jul 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com